The inhibition of new vessel formation by targeting VEGF signaling can retard tumor growth but the emergence of resistance to anti-VEGF agents, which often results in metastatic recurrence, has limited therapeutic success [5,6,7]. The gene discussed is VEGFA; the disease is neoplasm.